Longeveron appoints Stephen Willard as CEO

Longeveron Inc. (NASDAQ: LGVN) announced that its board of directors appointed Stephen H. Willard as chief executive officer, effective February 11. Willard succeeds Than Powell, who served as interim CEO and will remain with the company to support the leadership transition and continue business development activities.

Willard brings over 30 years of leadership experience in biotechnology and pharmaceutical companies. He previously served as CEO of ICAPATH Inc., NRx Pharmaceuticals Inc., Cellphire Inc., and Flamel Technologies S.A., a NASDAQ-traded biotech company where he served for seven years and was CFO before becoming CEO. He also served as chairman of Flamel's board and was a board member of E*Trade Financial Corporation.

The Miami-based clinical stage regenerative medicine company is developing cellular therapies for rare pediatric and chronic aging-related conditions. The company expects top-line results from its pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome in the third quarter of 2026.

"Our pivotal Phase 2b clinical trial evaluating laromestrocel as a potential treatment for HLHS is anticipated to produce top-line trial results in third quarter of this year," said Joshua Hare, executive chairman and chief science officer. "Longeveron has previously received FDA guidance that, if successful, this trial would be deemed a pivotal trial for purposes of BLA filing."

Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy. The company's investigational product laromestrocel has received five FDA designations across its development programs.

You May Also Be Interested In